FDA OKs Pivotal Trial Testing RheOx System in Chronic Bronchitis

FDA OKs Pivotal Trial Testing RheOx System in Chronic Bronchitis

287699

FDA OKs Pivotal Trial Testing RheOx System in Chronic Bronchitis

The U.S. Food and Drug Administration (FDA) has cleared the start of an international pivotal trial to test the RheOx System, Gala Therapeutics’ medical device, in adults with chronic obstructive pulmonary disease (COPD) who have moderate to severe chronic bronchitis. “Chronic bronchitis is a debilitating disease which results in symptoms that impact quality of life which commonly persist following guideline based medical treatment,” Frank Sciurba, MD, a co-principal investigator in the upcoming trial, said in a…

You must be logged in to read/download the full post.